<DOC>
	<DOC>NCT00490646</DOC>
	<brief_summary>The purpose of this randomized, Phase 2 open-label study was to assess the response rate of participants with Human Epidermal Growth Factor Receptor 2 (Her2+) locally advanced and/or metastatic breast cancer (not previously treated with chemotherapy or trastuzumab) to treatment with ixabepilone plus trastuzumab and/or docetaxel plus trastuzumab.</brief_summary>
	<brief_title>A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>Locally advanced or metastatic HER2+ breast cancer not previously treated with chemotherapy or trastuzumab. Subjects who had received prior (neo)adjuvant chemotherapy or trastuzumab were eligible except if they relapsed within 12 months after the last dose of a taxane or trastuzumab given as (neo)adjuvant therapy. Measurable disease Left Ventricular Ejection Fraction (LVEF) â‰¥50% Prior chemotherapy or trastuzumab for metastatic breast cancer (MBC) Relapse within 1 year after (neo)adjuvant taxane or trastuzumab Neuropathy &gt; Grade 1 Significant cardiovascular disease Any brain metastases</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Locally advanced and/or metastatic breast cancer</keyword>
</DOC>